Dogwood Therapeutics Total Current Liabilities 2020-2024 | DWTX

Dogwood Therapeutics total current liabilities from 2020 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.

Dogwood Therapeutics Total Current Liabilities 2020-2024 | DWTX

Dogwood Therapeutics total current liabilities from 2020 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$174.7B
Vertex Pharmaceuticals (VRTX)$125B
Regeneron Pharmaceuticals (REGN)$112.1B
Bristol Myers Squibb (BMY)$107B
Gilead Sciences (GILD)$106.8B
CSL (CSLLY)$97.4B
GSK (GSK)$80.7B
Alnylam Pharmaceuticals (ALNY)$36.9B
Argenex SE (ARGX)$32.6B
BioNTech SE (BNTX)$27.9B
Biogen (BIIB)$27.9B
Illumina (ILMN)$23.5B
Moderna (MRNA)$22B
BeiGene (BGNE)$21.7B
Genmab (GMAB)$15.3B
BioMarin Pharmaceutical (BMRN)$13.4B
Exact Sciences (EXAS)$12.9B
Vaxcyte (PCVX)$12.9B
Insmed (INSM)$12.8B
Incyte (INCY)$12.8B
Sarepta Therapeutics (SRPT)$11.8B
Bio-Techne Corp (TECH)$11.7B
QIAGEN (QGEN)$10B
Bio-Rad Laboratories (BIO.B)$9.3B
Roivant Sciences (ROIV)$8.8B
Legend Biotech (LEGN)$8.2B
Revolution Medicines (RVMD)$8.2B
Exelixis (EXEL)$8.1B
Repligen (RGEN)$8.1B
Intra-Cellular Therapies (ITCI)$7.9B